Kaesmann Lukas, Janssen Stefan, Schild Steven E, Rades Dirk
Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany.
Lung. 2016 Apr;194(2):295-8. doi: 10.1007/s00408-016-9857-4. Epub 2016 Feb 16.
The Charlson Comorbidity Index plus three comorbidity scales were evaluated for survival after radiochemotherapy of limited stage SCLC. For the Charlson Comorbidity Index, 2-4 points were compared to 5-8 points. For the Age-Comorbidity Score, 2-6 points were compared to 7-10 points. For the Medical Research Council (MRC) Breathlessness Scale, grades 0-2 were compared to grades 3-5. For the Simplified Comorbidity Score, 0-5 points were compared to 6-11 and 12-17 points. Charlson Comorbidity Index (p = 0.022) and MRC Breathlessness Scale (p < 0.001) showed significant associations with survival, the Age-Comorbidity Score a trend (p = 0.06). For the Simplified Comorbidity Score, no significant correlation was found (p = 0.54). Absolute differences in survival ≥20 % were observed for the MRC Breathlessness Scale at 1, 2, and 3 years, for the Charlson Comorbidity Index at 1 year, and for the Age-Comorbidity Score at 2 years. Thus, particularly the MRC Breathlessness Scale can contribute to personalization of the treatment of SCLC.
对局限性小细胞肺癌放化疗后的生存情况评估了查尔森合并症指数（Charlson Comorbidity Index）及三种合并症量表。对于查尔森合并症指数，将2 - 4分与5 - 8分进行比较。对于年龄合并症评分（Age-Comorbidity Score），将2 - 6分与7 - 10分进行比较。对于医学研究委员会（Medical Research Council，MRC）呼吸困难量表，将0 - 2级与3 - 5级进行比较。对于简化合并症评分，将0 - 5分与6 - 11分及12 - 17分进行比较。查尔森合并症指数（p = 0.022）和MRC呼吸困难量表（p < 0.001）与生存有显著关联，年龄合并症评分有一定趋势（p = 0.06）。对于简化合并症评分，未发现显著相关性（p = 0.54）。在1年、2年和3年时，MRC呼吸困难量表、1年时的查尔森合并症指数以及2年时的年龄合并症评分观察到生存绝对差异≥20%。因此，尤其是MRC呼吸困难量表有助于小细胞肺癌治疗的个体化。
